Clinical Trial Update: Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 clinical trial evaluating azacitidine (AZA) in combination with APG1252 for high-risk acute myeloid leukemia; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• APG1252
• AZA (azacitidine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: AML | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING